软膜
多重耐药
癌症
ATP结合盒运输机
阿霉素
癌症研究
肝癌
顺铂
药理学
癌细胞
运输机
医学
生物
抗药性
化疗
内科学
聚ADP核糖聚合酶
生物化学
遗传学
DNA
基因
聚合酶
作者
Lin Chang,Yunlong Hou,Lili Zhu,Zhixue Wang,Guotao Chen,Chengfeng Shu,Yali Liu
标识
DOI:10.1016/j.bbrc.2019.10.141
摘要
Overexpression of ATP-binding cassette (ABC) transporter is one of the most important factors taking responsibility for the progress of multidrug resistance (MDR) in multiple cancers. In this study, we investigated that veliparib, a PARP inhibitor which is in clinical development, could overcome ABCB1-mediated MDR in liver cancer cells. Veliparib could significantly enhance the cytotoxic effects of a series of conventional chemotherapeutic drugs in ABCB1-overexpression liver cancer cells. Mechanism study showed that veliparib could significantly enhance the accumulation of doxorubicin in ABCB1-overexpression liver cancer cells, without down-regulating the expression level of ABCB1. Finally, veliparib could significantly inhibit the ATPase activity of ABCB1 transporter. This study could provide information that combine veliparib with other chemotherapeutic drugs may benefit liver cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI